These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 24983741)

  • 21. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Maute L; Grünwald V; Weikert S; Kube U; Gauler T; Kahl C; Burkholder I; Bergmann L
    J Cancer Res Clin Oncol; 2014 May; 140(5):823-7. PubMed ID: 24556802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
    Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
    Wong MK; Yang H; Signorovitch JE; Wang X; Liu Z; Liu NS; Qi CZ; George DJ
    Curr Med Res Opin; 2014 Apr; 30(4):537-45. PubMed ID: 24329572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
    Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
    Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
    World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current management of metastatic renal cell carcinoma: evolving new therapies.
    Kumar R; Kapoor A
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.